No Data
No Data
Neumora Therapeutics' Head of R&D Sells Over $490k in Company Stock
Neumora Therapeutics Analyst Ratings
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $23
Buy Rating on Neumora Therapeutics: Navigating Navacaprant's Potential in Neuropsychiatric Care
RBC Capital Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $29
RBC Capital Reaffirms Their Buy Rating on Neumora Therapeutics, Inc. (NMRA)